Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation

Bone Marrow Transplantation

Volumn 46, Issue 9, 2011, Pages 1167-1185

  Rowley, S D ^a   Donato, M L ^a   Bhattacharyya, P ^b  

^a John Theurer Cancer Center   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ABO incompatibility; allogeneic transplantation; hemolytic transfusion reaction; isoagglutinins; red cell antigens; transfusion support

Indexed keywords

AGGLUTININ; AZATHIOPRINE; B LYMPHOCYTE ANTIBODY; CALCINEURIN INHIBITOR; CYCLOSPORIN A; ERYTHROCYTE ANTIGEN; ERYTHROPOIETIN ANTIBODY; HLA ANTIGEN; METHOTREXATE; METHYLPREDNISOLONE; MINOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BIOCOMPATIBILITY; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP INCOMPATIBILITY; BLOOD TRANSFUSION REACTION; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ENGRAFTMENT; ERYTHROCYTE; ERYTHROCYTE APLASIA; ERYTHROCYTE TRANSFUSION; GENETIC DIFFERENCE; HEMOLYSIS; HLA MATCHING; HUMAN; MYELOABLATIVE CONDITIONING; NONHUMAN; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMAPHERESIS; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RELAPSE; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT PLANNING;

ABO BLOOD-GROUP SYSTEM; ANIMALS; BLOOD GROUP INCOMPATIBILITY; ERYTHROCYTES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 80052477363     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.135     Document Type: Review

References (136)

1. Mielcarek M, Leisenring W, Torok-Storb B, Storb R. Graftversus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Blood 2000; 96: 1150-1156. (Pubitemid 30616887)
2. Kimura F, Sato K, Kobayashi S, Ikeda T, Sao H, Okamoto S et al. Impact of ABO-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program. Haematologica 2008; 93: 1686-1693.
3. Logdberg L, Reid ME, Zelinski T. Human blood group genes 2010: chromosomal locations and cloning strategies revisited. Transfus Med Rev 2011; 25: 36-46.
4. Ried ME, Lomas-Francis C. The Blood Group Antigen Facts Book, 2nd edn. Elsevier Academic Press: New York, 2004.
5. Franchini M, de Gironcoli M, Gandini G, Vassanelli A, Rocca P, Benedetti F et al. Transmission of an anti-RhD alloantibody from donor to recipient after ABO-incompatible BMT. Bone Marrow Transplant 1998; 21: 1071-1073. (Pubitemid 28230675)
6. Leo A, Mytilineos J, Voso MT, Weber-Nordt R, Liebish P, Lensing C et al. Passenger lymphocyte syndrome with severe hemolytic anemia due to an anti-Jka after allogeneic PBPC transplantation. Transfusion 2000; 40: 632-636. (Pubitemid 30413313)
7. Seebach JD, Stussi G, Passweg JR, Loberiza FR, Gajewski JL, Keating A et al. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant 2005; 11: 1006-1013. (Pubitemid 41754719)
8. Michallet M, Le Q-H, Mohty M, Prebet T, Nicolini R, Boiron JM et al. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Exp Hematol 2008; 36: 535-544.
9. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 2043-2051.
10. Canals C, Muniz-Diaz E, Martinez C, Martino R, Moreno I, Ramos A et al. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantations afterreduced intensity conditioning. Transfusion 2004; 44: 1603-1611. (Pubitemid 39431280)
11. Worel N, Kalhs P, Keil F, Prinz E, Moser K, Schulenberg A et al. ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation. Transfusion 2003; 43: 1153-1161. (Pubitemid 37022378)
12. Kim JG, Sohn SK, Kim DH, Baek JH, Lee KB, Min WS et al. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2005; 35: 489-495. (Pubitemid 40403352)
13. Gale RP, Feig S, Ho W, Falk P, Rippee C, Sparkes R. ABO blood group system and bone marrow transplantation. Blood 1977; 50: 185-194. (Pubitemid 8140391)
14. Buckner CD, Clift RA, Sanders JE, Williams B, Gray M, Storb R et al. ABO-incompatible marrow transplants. Transplantation 1978; 26: 233-238. (Pubitemid 9113393)
15. Bensinger WI, Buckner CD, Thomas ED, Clift RA. ABOincompatible marrow transplants. Transplantation 1982; 33: 427-429.
16. Bacigalupo A, Van Lint MT, Occhini D, Ferrari G, Pittaluga PA, Frassoni F et al. ABO compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation. Transplantation 1988; 45: 1091-1094.
17. Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D et al. Analysis of risk factors for the development of GvHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Biol Blood Marrow Transplant 2001; 7: 620-630. (Pubitemid 33130595)
18. Benjamin RJ, McGurk S, Ralston MS, Churchill WH, Antin JH. ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. Transfusion 1999; 39: 178-187.
19. Helming AM, Brand A, Wolterbeek R, van Tol MJ, Egeler RM, Ball LM. ABO incompatible stem cell transplantation in children does not influence outcome. Pediatr Blood Cancer 2007; 49: 313-317. (Pubitemid 47236222)
20. Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Saso R et al. Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia? Bone Marrow Transplant 2002; 29: 853-859. (Pubitemid 34679231)
21. Tomonari A, Takahashi S, Ooi J, Tsukada N, Konuma T, Kobayashi T et al. Impact of ABO incompatibility on engraftment and transfusion requirement after unrelated cord blood transplantation: a single institute experience in Japan. Bone Marrow Transplant 2007; 40: 523-528. (Pubitemid 47382121)
22. Wang Z, Sorror ML, Leisenring W, Schoch G, Maloney DG, Sandmaier BM et al. The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation. Br J Haematol 2010; 149: 101-110.
23. Resnick IB, Tsirigotis PD, Shapira MY, Aker M, Bitan M, Samuel S et al. ABO incompatibility is associated with increased non-relapse and GvHD mortality in patients with malignancies treated with a reduced intensity regimen: a single center experience of 221 patients. Biol Blood Marrow Transplant 2008; 14: 409-417. (Pubitemid 351372745)
24. Storb R, Prentice RL, Thomas ED. Marrow Transplantation for treatment of aplastic anemia. An analysis of factors associated with gaft rejection. N Engl J Med 1977; 296: 61-66. (Pubitemid 8017136)
25. Stussi G, Muntwyler J, Passweg JR, Seebach L, Schanz U, Gmur J et al. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30: 87-93.
26. Erker CG, Steins MB, Fischer R-J, Kienast W, Berdel WE, Sibrowski Wet al. The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation. Transfusion 2005; 45: 1382-1390. (Pubitemid 41647807)
27. Blin N, Traineau R, Houssin S, Peffault de LaTour R, Petropoulou A, Robin M et al. Impact of donor-recipient ABO mismatch on allogeneic transplantation outcome according to stem cell source. Biol Blood Marrow Transplant 2010; 16: 1315-1323.
28. Ozkurt ZN, Yegin ZA, Yenicesu I, Aki SZ, Yagci M, Sucak GT. Impact of ABO-incompatible donor on early and late outcome of hematopoietic stem cell transplantation. Transplant Proc 2009; 41: 3851-3858.
29. Kalacioglu M, Copelan E, Avalos B, Klein J, Goormastic M, Bolwell B. Survival after ABO-incompatible allogeneic bone marrow transplant after a preparative regimen of busulfan and cyclophosphamide. Bone Marrow Transplant 1995; 15: 105-110.
30. Klummp TR, Herman JH, Ulicny J, Emmons RVB, Martin ME, Mangin KF. Lack of effect of donor-recipient ABO mismatching on outcome following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38: 615-620. (Pubitemid 44596853)
31. Goldman J, Liesveld J, Nichols D, Heal J, Blumberg N. ABO incompatibility between donor and recipient and clinical outcomes in allogeneic stem cell transplantation. Leuk Res 2003; 27: 489-491. (Pubitemid 36315779)
32. Rozman P, Kosir A, Bohinjec M. Is the ABO incompatibility a risk factor in bone marrow transplantation? Transplant Immunol 2005; 14: 159-169. (Pubitemid 40848521)
33. Kanda J, Ichinohe T, Matsuo K, Benjamin RJ, Klumpp TR, Rozman P et al. Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies; IPD-based meta-analysis of cohort studies. Transfusion 2009; 49: 624-635.
34. Adams BR, Miller AN, Costa LJ. Self-limited hemolysis due to anti-D passenger lymphocyte syndrome in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2010; 45: 772-773.
35. Loren AW, Bunin GR, Boudreau C, Champlin RE, Cnaan A, Horowitz MM et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 758-769. (Pubitemid 43899412)
36. Daniel-Johnson J, Leitman S, Klein H, Alter H, Lee-Stroka A, Scheinberg P et al. Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactions. Transfusion 2009; 49: 1845-1849.
37. Olsson MJ, Chester MA. Polymorphism and recombination events at the ABO locus: a major challenge for genomic ABO blood grouping strategies. Transfus Med 2001; 11: 295-313. (Pubitemid 32771923)
38. Eiz-Vesper B, Seltsam A, Blasczyk R. ABO glycosyltransferases as potential source of minor histocompatibility antigens in allogeneic peripheral blood progenitor cell transplantation. Transfusion 2005; 45: 960-968. (Pubitemid 40798788)
39. Daniels G. Functions of red cell surface proteins. Vox Sang 2007; 93: 331-340. (Pubitemid 350135079)
40. Cartron JP, Colin Y. Structural and functional diversity of blood group antigens. Transfus Clin Biol 2001; 8: 163-199. (Pubitemid 32672970)
41. Weiden PL, Storb R, Thomas ED, Graham TC, Lerner KG, Buckner CD et al. Preceding transfusions and marrow graft rejection in dogs and man. Transplant Proc 1976; 8: 551-554. (Pubitemid 8006521)
42. Storb R, Thomas ED, Buckner CD, Clift RA, Deeg HJ, Fefer A et al. Marrow transplantation in thirty 'untransfused' patients with severe aplastic anemia. Ann Intern Med 1980; 92: 30-36. (Pubitemid 10135220)
43. Storb R, Weiden PL, Deeg HJ, Graham TC, Atkinson K, Slichter SJ et al. Rejection of marrow from DLA-identical canine littermates given transfusions before grafting: antigens involved are expressed on leukocytes and skin epithelial cells but not on platelets and red blood cells. Blood 1979; 54: 477-484. (Pubitemid 9247716)
44. Desmerets M, Cadwell CM, Peterson KR, Neades R, Zimring JC. Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model. Blood 2009; 114: 2315-2322.
45. Patel SR, Cadwell CM, Medford A, Zimring JC. Transfusion of minor histocompatibility antigen-mismatched platelets induces rejection of bone marrow transplants in mice. J Clin Invest 2009; 119: 2787-2794.
46. Bean MA, Storb R, Graham T, Raff T, Sale GE, Schuening F et al. Prevention of transfusion-induced sensitization to minor histocompatibility antigens on DNA-identical canine marrow grafts by gamma irradiation of marrow donor blood. Transplantation 1991; 52: 956-960.
47. Bean MA, Graham T, Appelbaum FR, Deeg HJ, Schuening F, Sale GE et al. Gamma-irradiation of pretransplant blood transfusions from unrelated donors prevents sensitization to minor histocompatibility antigens on dog leukocyte antigenidentical canine marrow grafts. Transplantation 1994; 57: 423-426.
48. Rozman P, Karas M, Kosir A, Labar B, Madrigal A, Middleton D et al. Are human platelet alloantigens (HPA) minor transplantation antigens in clinical bone marrow transplantation? Bone Marrow Transplant 2003; 31: 497-506. (Pubitemid 36511818)
49. Cooling LL, Kelly K, Barton J, Hwang D, Koerner TA, Olson JD. Determinants of ABH expression on human blood platelets. Blood 2005; 105: 3356-3364.
50. Weissinger F, Sandmaier BM, Maloney DG, Bensinger WI, Golley T, Storb R et al. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cells transplants from HLA-identical siblings. Blood 2001; 98: 3584-3588.
51. Remberger M, Watz E, Ringden O, Mattson J, Shanwell A, Wikman A. Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 675-681.
52. Badros A, Tricot G, Toor A, Morris C, Guo C, Munshi N et al. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion 2002; 42: 205-209.
53. Ravn V, Dabelsteen E. Tissue distribution of histo-blood group antigens. APMIS 2000; 108: 1-28. (Pubitemid 30090251)
54. Ting A, Pun A, Dodds AJ, Atkinson K, Biggs JC. Red cell alloantibodies produced after bone marrow transplantation. Transfusion 1987; 27: 145-147. (Pubitemid 17101777)
55. Abou-Elella AA, Camarillo TA, Allen MB, Barclay S, Pierce JA, Holland HK et al. Low incidence of red cell and HLA antibody formation by bone marrow transplant patients. Transfusion 1995; 35: 931-935. (Pubitemid 26141046)
56. de la Rubia J, Arriaga F, Andreu R, Sanz G, Jimenez C, Vicente A et al. Development of non-ABO RBC alloantibodies in patients undergoing allogeneic HPC transplantation. Is ABO incompatibility a predisposing factor? Transfusion 2001; 41: 106-110. (Pubitemid 32142254)
57. Zupanska B, Saucha MJ, Michalewska B, Malinowska A, Brojer E, Hellmann A. Multiple red cell alloantibodies, including anti-Dib, after allogeneic ABO-matched peripheral blood progenitor cell transplantation. Transfusion 2005; 45: 16-20.
58. Lopez A, de la Rubia J, Arriaga F, Jimenez C, Sanz GF, Carpio N et al. Severe hemolytic anemia due to multiple red cell alloantibodies after an ABO-incompatible allogeneic bone marrow transplant. Transfusion 1998; 38: 247-251. (Pubitemid 28180643)
59. Young PP, Goodnough LT, Westervelt P, Dipersio JF. Immune hemolysis involving non-ABO/RhD alloantibodies following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 1305-1310. (Pubitemid 32655400)
60. Wirk B, Klumpp TR, Ulicny J, Herman JH, Gajewski JL, Martin ME et al. Lack of effect of donor-recipient Rh mismatch on outcomes after allogeneic hematopoietic stem cell transplantation. Transfusion 2008; 48: 163-168.
61. Korbling M, Huh YO, Durett A, Mirza N, Miller P, Engel P et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995; 86: 2842-2848.
62. Larghero J, Rea D, Esperou H, Biscay N, Maurer MN, Lacassangne M et al. ABO-mismatched marrow processing for transplantation: results of 114 procedures and analysis of immediate adverse events and hematopoietic recovery. Transfusion 2006; 46: 398-402. (Pubitemid 43334093)
63. Rubinstein P, Dobrila L, Rosenfield RE, Adamson JW, Migliaccio G, Migliaccio AR et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA 1995; 92: 10119-10122.
64. Rowley SD, Prather K, Bui KT, Appel M, Felt T, Bensinger WI. Collection of peripheral blood progenitor cells with an automated leukapheresis system. Transfusion 1999; 39: 1200-1206.
65. Snell M, Chau C, Hendrix D, Fox R, Downes KA, Creger R et al. Lack of isohemagglutinin production following minor ABO incompatible unrelated HLA mismatched umbilical cord blood transplantation. Bone Marrow Transplant 2006; 38: 135-140.
66. Janatpour KA, Kalmin ND, Jensen HM, Holland PV. Clinical outcomes of ABO-incompatible RBC transfusions. Am J Clin Pathol 2008; 129: 276-281. (Pubitemid 352029318)
67. Stroncek DF, Clay ME, Smith J, Herr S, Ilstrup SJ, Kunkel LA et al. Composition of peripheral blood progenitor cell components collected from healthy donors. Transfusion 1997; 37: 411-417. (Pubitemid 27193555)
68. Scholl S, Klink A, Mugge L-O, Schilling K, Hoffken K, Sayer HG. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch. Transfusion 2005; 45: 1676-1683.
69. Braine HG, Sensenbrenner LL, Wright SK, Tutschka PJ, Saral R, Santos GW. Bone marrow transplantation with major ABO blood group incompatibility using erythrocyte depletion of marrow prior to infusion. Blood 60; 1982: 420-425. (Pubitemid 12048688)
70. Warkentin PI, Hilden JM, Kersey JH, Ramsay NK, McCullough J. Transplantation of major ABO-incompatible bone marrow depleted of red cells by hydroxyethyl starch. Vox Sang 1985; 48: 89-104. (Pubitemid 15196058)
71. Tsang KS, Li CK, Wong AP, Leung Y, Lau TT, Li K et al. Processing of major ABO-incompatible bone marrow for transplantation by using dextran sedimentation. Transfusion 1999; 39: 1212-1219.
72. Bensinger WI, Buckner CD, Clift RA, Thomas ED. Plasma exchange and plasma modification for the removal of anti-red cell antibodies prior to ABO-incompatible marrow transplant. J Clin Apher 1987; 3: 174-177.
73. Stussi G, Halter J, Bucheli E, Valli PV, Seebach L, Gmur J et al. Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins. Haematologica 2009; 94: 239-248.
74. Tobian AAR, Shirey RS, Montgomery RA, Tisch DJ, Ness PM, King KE. Therapeutic plasma exchange reduces ABO titers to permit ABO-incompatible renal transplantation. Transfusion 2009; 49: 1248-1254.
75. Geyer M, Fischer K-G, Drognitz O, Walz G, Pisarski P, Wilpert J. ABO-incompatible kidney transplantation with antigen-specific immunoadsorption and rituximab-insights and uncertainties. Contrib Nephrol 2009; 162: 47-60.
76. Rowley SD, Liang PS, Ulz L. Transplantation of ABOincompatible bone marrow and peripheral blood stem cell components. Bone Marrow Transplant 2000; 26: 749-757.
77. Lee JH, Lee JH, Choi SJ, Kim S, Seol M, Kwon SW et al. Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. Br J Haematol 2003; 120: 702-710. (Pubitemid 36255875)
78. Bolan CD, Leitman SF, Griffith LM, Wesley RA, Procter JL, Stroncek DR et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood 2001; 98: 1687-1694.
79. Southcott MJ, Tanner MJ, Anstee DJ. The expression of human blood group antigens during erythropoiesis in a cell culture system. Blood 1999; 93: 4425-4435. (Pubitemid 29279286)
80. Bony V, Gane P, Bailly P, Cartron JP. Time-course expression of polypeptides carrying blood group antigens during human erythroid differentiation. Br J Haematol 1999; 107: 263-274. (Pubitemid 29530210)
81. Helbig G, Stella-Holowiecka B, Krawczyk-Kulis M, Wojnar J, Markiewicz M, Wojciechowska-Sadus M et al. Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukemia. Haematologica 2005; 90: e93-e96.
82. Dahl D, Hahn A, Koenecke C, Heuft HG, Dammann E, Stadler M et al. Prolonged isolated red blood cell transfusion requirement after allogeneic blood stem cell transplantation: identification of patients at risk. Transfusion 2010; 50: 649-655.
83. Griffith LM, McCoy JP, Bolan CD, Stroncek DF, Pickett AC, Linton GF et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol 2005; 128: 668-675. (Pubitemid 40343237)
84. Schetelig J, Breitschaft A, Kroger N, Zabelinn T, Ebell W, Bornhauser M et al. After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B. Transfusion 2005; 45: 779-787. (Pubitemid 40656393)
85. Maciej Zaucha J, Mielcarek M, Takatu A, Little MT, Gooley T, Baker J et al. Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation. Br J Haematol 2002; 119: 740-750. (Pubitemid 35366217)
86. Gmur JP, Burger J, Schaffner A, Neftel K, Oelz O, Frey D et al. Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood 1990; 75: 290-295. (Pubitemid 20031523)
87. Heyll A, Aul C, Runde V, Arning M, Schneider W, Wernet P. Treatment of pure red cell aplasia after major ABOincompatible bone marrow transplantation with recombinant erythropoietin. Blood 1991; 77: 906.
88. Santamaria A, Sureda A, Martino R, Domingo-Albos A, Muniz-Diaz E, Brunet S. Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin. Bone Marrow Transplant 1997; 20: 1105-1107. (Pubitemid 28043426)
89. Paltiel O Cournoyer D, Rybka W. Pure red cell aplasia following ABO-incompatible bone marrow transplantation: response to erythropoietin. Transfusion 1993; 33: 418-421. (Pubitemid 23144026)
90. Benjamin RJ, Connors JM, McGurk S, Churchill WH, Antin JH. Prolonged erythroid aplasia after major ABO-mis-matched transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant 1998; 4: 151-156. (Pubitemid 128538806)
91. Maschan AA, Skorobogatova EV, Balashov DN, Pashanov ED, Trakhtman PE, Schipitzina IP et al. Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cells transplantation for acquired aplastic anemia. Bone Marrow Transplant 2002; 30: 405-407. (Pubitemid 35203515)
92. Sora F, De Matteis S, Piccirillo N, Chiusolo P, Laurenti L, Putzulu et al. Rituximab for pure red cell aplasia after ABOmismatched allogeneic peripheral blood progenitor cell transplantation. Transfusion 2005; 45: 643-644.
93. Zand MS. B-cell activity of polyclonal antithymocyte globulins. Transplantation 2006; 82: 1387-1395. (Pubitemid 44967615)
94. Labar B, Bogdanic V, Nemet D, Kovacevic-Metelko J, Mrsic M, Pavletic Z et al. Antilymphocyte globulin for treatment of pure red cell aplasia after major ABO incompatible marrow transplant. Bone Marrow Transplant 1992; 10: 471-472.
95. Bierman PJ, Warkentin P, Hutchins MR, Klassen LW. Pure red cell aplasia following ABO mismatched marrow transplantation for chronic lymphocyte leukemia: response to antithymocyte globulin. Leuk Lymphoma 1993; 9: 169-171. (Pubitemid 23141058)
96. Roychowdhury DF, Linker CA. Pure red cell aplasia complicating an ABO-compatible allogeneic bone marrow transplantation, treated successfully with antithymocyte globulin. Bone Marrow Transplant 1995; 16: 471-472.
97. Verholen F, Stalder M, Heig C, Chalandon Y. Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion. Eur J Haematol 2004; 73: 441-446. (Pubitemid 39564369)
98. Ebihara Y, Manabe A, Tsuruta T, Ishikawa K, Haseqawa D, Ohtsuka Y et al. The effect of donor leukocyte infusion on refractory pure red blood cell aplasia after allogeneic stem cell transplantation in a patient with myelodysplastic syndrome developing from Kostmann Syndrome. Int J Hematol 2007; 86: 446-450.
99. Ramsey G, Smietana SJ. Long-term follow-up of red cell alloantibodies. Transfusion 1994; 34: 122-124. (Pubitemid 24059105)
100. Happ WM. Appearance of isoagglutinins in infants and children. J Exp Med 1920; 29: 313-314.
101. Rowley S, Braine H. Probable hemolysis following minor ABO incompatible marrow transplantation. Blood 1982; 60: 171a.
102. Moog R, Melder C, Prumbaum M, Muller N, Schaefer UW. Rapid donor type isoagglutinins production after allogeneic peripheral progenitor cell transplantation. Beitr Infusions Ther Transfus Med 1997; 34: 150-152.
103. Hoegler W, Nachbauer D, Kropshofer G, Wehl G, Schoenitzer D, Nussbaumer W. Abrupt onset of severe passenger lymphocyte syndrome after HLA-mismatched unrelated bone marrow transplantation in a seven-year-old boy. Med Pediatr Oncol 2002; 38: 143-144. (Pubitemid 34113454)
104. Greeno EW, Perry EH, Ilstrup SJ, Weisdorf DJ. Exchange transfusion the hard way: massive hemolysis following transplantation of bone marrow with minor ABO incompatibility. Transfusion 1996; 36: 71-74. (Pubitemid 26057267)
105. Reed M, Yearsley M, Krugh D, Kennedy M. Severe hemolysis due to passenger lymphocyte syndrome after hematopoietic stem cell transplantation from an HLAmatched related donor. Arch Pathol Lab Med 2003; 127: 1366-1368. (Pubitemid 37248339)
106. Curtin NJ, Schwarer AP. Nonmyeloablative peripheral blood stem cell transplant for T-cell prolymphocytic leukaemia complicated by fulminant haemolysis and acute renal failure at engraftment secondary to minor ABO incompatibility. Clin Lab Haem 2005; 27: 206-208. (Pubitemid 40827549)
107. Hows J, Beddow K, Gordon-Smith E, Branch DR, Spruce W, Sniecinski I et al. Donor-derived red blood cell antibodies and immune hemolysis after allogeneic bone marrow transplantation. Blood 1986; 67: 177-181. (Pubitemid 16167029)
108. Nair V, Sharma A, Ratheesh J, Das S, Mishra DK, Kale R et al. Severe intravascular haemolysis following minor group mismatched peripheral blood stem cell transplantation. Bone Marrow Transplant 2007; 39: 805-806. (Pubitemid 46901980)
109. Tiplady CW, Fitzgerald JM, Jackson GH, Conn JS, Proctor SJ. Massive haemolysis in a group A recipient of a group O peripheral blood stem cell allogeneic transplant. Transfus Med 2001; 11: 455-458. (Pubitemid 34044856)
110. Noborio K, Muroi K, Izumi T, Toshima M, Kawano-Yamamoto C, Otsuki T et al. Massive immune hemolysis after non-myeloablative allogeneic peripheral blood stem cell transplantation with minor ABO-incompatibility. Leuk Lymph 2003; 44: 357-359.
111. Lee HJ, Gulbis A, DePadua Silva L, Hosing C, Khouri I, deLima M et al. Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT. Bone Marrow Transplant 2008; 42: 67-69. (Pubitemid 352003429)
112. Salmon JP, Michaux S, Hermanne JP, Baudoux E, Gerard C, Sontag-Thull D et al. Delayed massive immune hemolysis mediated by minor ABO incompatibility after allogeneic peripheral blood progenitor cell transplantation. Transfusion 1999; 39: 369-373.
113. Laurencet FM, Samii K, Bressoud A, Tajeddin M, Easton J, Stelling MJ et al. Massive delayed hemolysis following peripheral blood stem cell transplantation with minor ABO incompatibility. Hematol Cell Ther 1997; 39: 159-162. (Pubitemid 27314668)
114. Bornhauser M, Ordemann R, Paaz U, Schuler U, Kompf J, Holig K et al. Rapid engraftment after allogeneic ABOincompatible peripheral blood progenitor cell transplantation complicated by severe hemolysis. Bone Marrow Transplant 1997; 19: 295-297. (Pubitemid 27077489)
115. Bolan CD, Childs RW, Procter JL, Barrett AJ, Leitmann SF. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. Br J Haemataol 2001; 112: 787-795. (Pubitemid 32222854)
116. Toren A, Dacosta Y, Manny N, Varadi G, Or R, Nagler A. Passenger B-lymphocyte-induced severe hemolytic disease after allogeneic peripheral blood stem cell transplantation (letter). Blood 1996; 87: 843-844. (Pubitemid 26030345)
117. Oziel-Taieb S, Faucher-Barbey C, Chabannon C, Ladaique P, Saux P, Souin F et al. Early and fatal immune haemolysis after so-called 'minor' ABO-incompatible peripheral blood stem cell allotransplantation. Bone Marrow Transplant 1997; 19: 1155-1156. (Pubitemid 27267742)
118. Gajewski JL, Petz LD, Calhoun L, O'Rourke S, Landaw EM, Lyddane NR et al. Hemolysis of transfused group O red blood cells in minor ABO-incompatible unrelated-donor bone marrow transplants in patients receiving cyclosporine without posttransplant methotrexate. Blood 1992; 79: 3076-3085.
119. Worel N, Greinix HT, Keil F, Mittenbauer M, Lechner K, Fischer G et al. Severe immune hemolysis after minor ABOmismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning. Transfusion 2002; 42: 1293-1301.
120. Lapierre V, Oubouxar N, Auperin A, Tramalloni D, Tayebi H, Robinet E et al. Influence of the hematopoietic stem cell source on early immunohematologic reconstitution after allogeneic transplantation. Blood 2001; 97: 2580-2586.
121. Worel N, Greinix HT, Supper V, Leitner G, Mitterbauer M, Rabitsch W et al. Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABOmismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning. Transfusion 2007; 47: 1494-1502. (Pubitemid 47101075)
122. Josephson CD, Castillejo MI, Grima K, Hillyer CD. ABOmismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies. Transfus Apher Sci 2010; 42: 83-88.
123. Josephson CD, Mullis NC, Van Demark C, Hillyer CD. Significant number of apheresis-derived group O platelets units have 'high titer' anti-A/A,B: Implications for transfusion policy. Transfusion 2004; 44: 805-808. (Pubitemid 38738406)
124. Garraty G. Problems associated with passively transfused blood group alloantibodies. Am J Clin Pathol 1998; 109: 769-777.
125. Lapierre V, Kuentz M, Tiberghien P, for Societe Francaise de Greffe de Moelle. Allogeneic peripheral blood hematopoietic stem cell transplantation: guidelines for red blood cell immuno-hematological assessment and transfusion practice. Bone Marrow Transplant 2000; 25: 507-512. (Pubitemid 30137865)
126. Heddle NM, O'Hoski P, Singer J, McBride JA, Ali MA, Kelton JG. A prospective study to determine the safety of omitting the antiglobulin crossmatch from pretransfusion testing. Br J Haematol 1992; 81: 579-584.
127. Judd WJ, Fullen DR, Steiner EA, Cavenport RD, Knafl PC. Revisiting the issue: can the reading for serologic reactivity following 37 degrees C incubation be omitted? Transfusion 1999; 39: 295-299.
128. Chapman JF, Milkins C, Voak D. The computer crossmatch: a safe alternative to the serological crossmatch. Transfus Med 2000; 10: 251-256. (Pubitemid 32062540)
129. McLeod BC, Piehl MR, Sassetti RJ. Alloimmunizaation to RhD by platelet transfusion in autologous bone marrow transplant recipients. Vox Sang 1990; 59: 185-189. (Pubitemid 20332877)
130. Asfour M, Narvios A, Lichtiger B. Transfusion of RhDincompatible blood components in RhD-negative blood marrow transplant recipients. Med Gen Med 2004; 6: 22.
131. Mijovic A. Alloimmunization to RhD antigen in RhDincompatible haemopoietic cell transplants with non-myeloablative conditioning. Vox Sang 2002; 83: 358-362. (Pubitemid 35434359)
132. Avache S, Herman JH. Prevention of D sensitization after mismatched transfusion of blood components: toward optimal use of RhIG. Transfusion 2008; 48: 1990-1999.
133. Heal JM, Liesveld JL, Phillips GL, Blumberg N. What would Karl Landsteiner do? The ABO blood group and stem cell transplantation. Bone Marrow Transplant 2005; 36: 747-755. (Pubitemid 41613297)
134. Lapierre V, Mahe C, Auperin A, Stambouli F, Oubouzar N, Tramalloni D et al. Platelet transfusion containing ABOincompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children. Transplantation 2005; 80: 314-319. (Pubitemid 41129959)
135. International Standards for Cellular Therapy Product Collection. Processing, and Administration, 4th edn. Foundation for the Accreditation of Cellular Therapy: Omaha, NE.
136. Raimondi R, Soli M, Lamparelli T, Bacigalupo A, Arcese W, Belloni M et al. ABO-incompatible bone marrow transplantation: a GITMO survey of current practice in Italy and comparison with the literature. Bone Marrow Transplant 2004; 34: 321-329. (Pubitemid 39172439)